Blog
RSS FeedPosted by Michael Wonder on 24 Aug 2021
Clovis Oncology announces availability of and reimbursement for Rubraca (rucaparib) tablets for women with relapsed ovarian cancer in Switzerland
24 August 2021 - Rubraca is commercially available in Germany, United Kingdom, Italy, Spain, France, Netherlands, United States of America and ...
Posted by Michael Wonder on 21 Apr 2020
Swiss deal on cystic fibrosis drugs could change price negotiations
21 April 2020 - The deal is expected to help 400 eligible cystic fibrosis patients in Switzerland. ...
Posted by Michael Wonder on 22 May 2018
'The Swiss government must make lifesaving drugs affordable'
22 May 2018 - Swiss health NGO Public Eye has launched a campaign calling for Swiss authorities to combat the ...
Posted by Michael Wonder on 04 Sep 2015
Novartis wins EU approval for multiple myeloma drug Farydak
4 September 2015 - Novartis AG said on Friday it received European Union approval for Farydak, a treatment for multiple myeloma ...
Posted by Michael Wonder on 03 Sep 2015
ALK obtains European approval for its house dust mite sublingual allergy immunotherapy tablet against allergic rhinitis and allergic asthma
31 August 2015 - ALK today announced that it has successfully completed the registration procedure for its house dust mite (HDM) ...
Posted by Michael Wonder on 03 Sep 2015
Novartis receives EU approval for new Revolade use as first-in-class therapy for patients with severe aplastic anemia
2 September 2015 - Novartis announced today that the European Commission has approved Revolade (eltrombopag olamine) for the treatment of adults ...
Posted by Michael Wonder on 02 Sep 2015
Europe gets Amgen cholesterol drug for 50-60 pct of U.S. price
1 September 2015 - Amgen is launching its injectable cholesterol drug in Europe at around half the U.S. price, in a ...
Posted by Michael Wonder on 01 Sep 2015
European Commission grants marketing authorisation for Strensiq (asfotase alfa) for the treatment of patients with paediatric-onset hypophosphatasia (HPP)
1 September 2015 - Alexion Pharmaceuticals, Inc. announced today that the European Commission has approved Strensiq (asfotase alfa) for long-term enzyme ...
Posted by Michael Wonder on 01 Sep 2015
European Commission grants marketing authorisation for Kanuma (sebelipase alfa) for the treatment of patients of all ages with lysosomal acid lipase deficiency (LAL-D)
1 September 2015 - Alexion Pharmaceuticals, Inc. announced today that the European Commission (EC) has approved Kanuma (sebelipase alfa) for long-term ...